March 14, 2025

AGC Biologics Honored for Excellence in Contract Development and Manufacturing

AGC Biologics Honored for Excellence in Contract Development and Manufacturing

Today, we announced that our company won two awards from the annual CDMO Leadership Awards, sponsored by Outsourced Pharma and Life Science Connect. AGC Biologics was named a winner in both the “Biologics – Global” and “Cell & Gene – Global” categories and is one of the few in the industry that scored high enough to be honored in multiple categories.

The awards are decided through survey-based scoring and focus on performance metrics across important areas such as facilities, innovation, scientific expertise, on-time delivery, seamless delivery across phases, manufacturing capabilities, and quality management systems. The program independently surveys leading global biopharma and biotechnology organizations to tabulate scores and uses feedback from only experienced industry leaders to decide the best CDMOs in the world.

“We are honored that our customers and industry leaders have confidence in our global CDMO services for biologics and cell and gene therapies,” said Alberto Santagostino, CEO and President, AGC Biologics. “AGC Biologics remains committed to offering friendly and expert CDMO services and being a collaborative partner. This is what we stand for. We aim to be a safe harbor for our Biopharma companies to help bring life-changing treatments to patients around the globe.”

AGC Biologics’ global biologics and cell and gene network spans three continents and is backed by 30 years of science, with more than 250 customers supported across 400 projects, 25 commercial products launched, and over 90 regulatory inspections achieved.

“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the Outsourcing community, and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” says Outsourced Pharma Chief Editor Louis Garguilo. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs. The unveiling of the award champions during our celebration in March will be an exciting new addition to the festivities.”

Our latest News

discover more
New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

Nagel, A.; Hass, E.W.; Hayes, H.; Huelbes, L.; Oliveira, S.; Hardin, H.M.; Marasigan, M.; Nisenbaum, E.; Misztal, C.; Telischi, F.F.; et al. Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636. https://doi.org/10.3390/ijms27062636 https://www.mdpi.com/1422-0067/27/6/2636 Simple Summary This study focuses on the action of fimepinostat, a dual histone deacetylase (HDAC)/phosphosphoinositide-3 kinase […]

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Technology transfer that works: At the “European Robotics Forum” (ERF) in late March, the trio of applicants won the prestigious award. The award recognizes research that has found its way into industrial applications. The application focused on a “no-code” solution that allows companies to deploy cobots without specialized knowledge or significant welding effort, even for […]

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Paris and Tarrytown, NY, April 13, 2026. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp